Avanir submits Neurodex NDA
This article was originally published in Pharmaceutical Approvals Monthly
Avanir is requesting a priority review for use of its anti-excitatory therapy Neurodex (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The firm completed a rolling submission of the NDA for the neurological disorder June 29. A priority review designation would make approval possible before year end. Avanir previously estimated the U.S. PBA market at $500 mil.; the firm also indicated it planned to have 70 reps in place for launch (1Pharmaceutical Approvals Monthly September 2004, p. 13). PBA is a symptom complex secondary to multiple neurological conditions including Alzheimer's, Parkinson's, multiple sclerosis and stroke...
You may also be interested in...
Avanir will meet with FDA "within the next few weeks" to discuss delays in its NDA for Neurodex for treatment of pseudobulbar affect, the firm says
AstraZeneca and Avanir plan to begin development of reverse cholesterol transport enhancing compounds in late 2005 under a deal worth up to $340 mil., the firms announced July 11
Avanir could see action on its upcoming Neurodex NDA for the treatment of pseudobulbar affect by mid-2005; the firm plans to submit the application by the end of the year and will request priority review.